Literature DB >> 21882282

Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor.

Richard D Williams1, Reem Al-Saadi, Rachael Natrajan, Alan Mackay, Tasnim Chagtai, Suzanne Little, Sandra N Hing, Kerry Fenwick, Alan Ashworth, Paul Grundy, James R Anderson, Jeffrey S Dome, Elizabeth J Perlman, Chris Jones, Kathy Pritchard-Jones.   

Abstract

Anaplasia in Wilms tumor, a distinctive histology characterized by abnormal mitoses, is associated with poor patient outcome. While anaplastic tumors frequently harbour TP53 mutations, little is otherwise known about their molecular biology. We have used array comparative genomic hybridization (aCGH) and cDNA microarray expression profiling to compare anaplastic and favorable histology Wilms tumors to determine their common and differentiating features. In addition to changes on 17p, consistent with TP53 deletion, recurrent anaplasia-specific genomic loss and under-expression were noted in several other regions, most strikingly 4q and 14q. Further aberrations, including gain of 1q and loss of 16q were common to both histologies. Focal gain of MYCN, initially detected by high resolution aCGH profiling in 6/61 anaplastic samples, was confirmed in a significant proportion of both tumor types by a genomic quantitative PCR survey of over 400 tumors. Overall, these results are consistent with a model where anaplasia, rather than forming an entirely distinct molecular entity, arises from the general continuum of Wilms tumor by the acquisition of additional genomic changes at multiple loci.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21882282     DOI: 10.1002/gcc.20907

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  22 in total

1.  Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group.

Authors:  Ariadne H A G Ooms; Samantha Gadd; Daniela S Gerhard; Malcolm A Smith; Jaime M Guidry Auvil; Daoud Meerzaman; Qing-Rong Chen; Chih Hao Hsu; Chunhua Yan; Cu Nguyen; Ying Hu; Yussanne Ma; Zusheng Zong; Andrew J Mungall; Richard A Moore; Marco A Marra; Vicki Huff; Jeffrey S Dome; Yueh-Yun Chi; Jing Tian; James I Geller; Charles G Mullighan; Jing Ma; David A Wheeler; Oliver A Hampton; Amy L Walz; Marry M van den Heuvel-Eibrink; Ronald R de Krijger; Nicole Ross; Julie M Gastier-Foster; Elizabeth J Perlman
Journal:  Clin Cancer Res       Date:  2016-10-04       Impact factor: 12.531

Review 2.  Wilms tumor.

Authors:  Andrew M Davidoff
Journal:  Adv Pediatr       Date:  2012

Review 3.  Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration.

Authors:  Jeffrey S Dome; Norbert Graf; James I Geller; Conrad V Fernandez; Elizabeth A Mullen; Filippo Spreafico; Marry Van den Heuvel-Eibrink; Kathy Pritchard-Jones
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

4.  Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group.

Authors:  Eric J Gratias; Lawrence J Jennings; James R Anderson; Jeffrey S Dome; Paul Grundy; Elizabeth J Perlman
Journal:  Cancer       Date:  2013-08-26       Impact factor: 6.860

Review 5.  Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma.

Authors:  Jennifer M Kalish; Leslie Doros; Lee J Helman; Raoul C Hennekam; Roland P Kuiper; Saskia M Maas; Eamonn R Maher; Kim E Nichols; Sharon E Plon; Christopher C Porter; Surya Rednam; Kris Ann P Schultz; Lisa J States; Gail E Tomlinson; Kristin Zelley; Todd E Druley
Journal:  Clin Cancer Res       Date:  2017-07-01       Impact factor: 12.531

Review 6.  Wilms' tumor: biology, diagnosis and treatment.

Authors:  Elwira Szychot; John Apps; Kathy Pritchard-Jones
Journal:  Transl Pediatr       Date:  2014-01

7.  N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.

Authors:  Adeline Berger; Nicholas J Brady; Rohan Bareja; Brian Robinson; Vincenza Conteduca; Michael A Augello; Loredana Puca; Adnan Ahmed; Etienne Dardenne; Xiaodong Lu; Inah Hwang; Alyssa M Bagadion; Andrea Sboner; Olivier Elemento; Jihye Paik; Jindan Yu; Christopher E Barbieri; Noah Dephoure; Himisha Beltran; David S Rickman
Journal:  J Clin Invest       Date:  2019-07-01       Impact factor: 14.808

8.  MYCN gene polymorphisms and Wilms tumor susceptibility in Chinese children.

Authors:  Xiaokai Huang; Jie Zhao; Jinhong Zhu; Shanshan Chen; Wen Fu; Xiaoqian Tian; Susu Lou; Jichen Ruan; Jing He; Haixia Zhou
Journal:  J Clin Lab Anal       Date:  2019-07-25       Impact factor: 2.352

Review 9.  The MYC oncogene - the grand orchestrator of cancer growth and immune evasion.

Authors:  Renumathy Dhanasekaran; Anja Deutzmann; Wadie D Mahauad-Fernandez; Aida S Hansen; Arvin M Gouw; Dean W Felsher
Journal:  Nat Rev Clin Oncol       Date:  2021-09-10       Impact factor: 66.675

10.  Array CGH Analysis of Paired Blood and Tumor Samples from Patients with Sporadic Wilms Tumor.

Authors:  Leila Cabral de Almeida Cardoso; Lara Rodriguez-Laguna; María Del Carmen Crespo; Elena Vallespín; María Palomares-Bralo; Rubén Martin-Arenas; Inmaculada Rueda-Arenas; Paulo Antonio Silvestre de Faria; Purificación García-Miguel; Pablo Lapunzina; Fernando Regla Vargas; Hector N Seuanez; Víctor Martínez-Glez
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.